• omega 3 for dry eyes

Effect of Oral Re-Esterified Omega-3


Oral nutri­tion is con­sid­ered pri­ma­ry ther­a­py for dry eyes and mei­bo­mi­an gland dys­func­tion. The pur­pose of this study was to assess the effect of oral re-ester­i­fied omega-3 fat­ty acids on tear osmo­lar­i­ty. MMP-9, OSDI, tear break-up time (TBUT), Schirmer’s score, corneal stain­ing and omega index.


This was a mul­ti­cen­ter, prospec­tive, inter­ven­tion­al, place­bo con­trolled, dou­ble masked, ran­dom­ized tri­al. On final analy­sis, 105 patients with dry eyes were ran­dom­ized to receive four cap­sules (2 gm) once a day con­tain­ing 1680 mg EPA and 560 mg DHA (PRN Dry Eye Omega Ben­e­fits) for 3 months or four cap­sules of place­bo. All patients under­went a screen­ing, base­line, 6 week and 12 weeks vis­it. On each vis­it patients were test­ed for tear osmo­lar­i­ty, MMP-9, flu­o­res­cein corneal stain­ing, Schirmer’s test­ing, and OSDI. On the screen­ing exam and week 12 eval­u­a­tion patients had their omega index test­ed.


Mean tear osmo­lar­i­ty at base­line, week 6 and week 12 was 326.0+15.4, 317.0+20.5 and 317.7+19.7 mOsm/L for the place­bo group ver­sus 326.2+15.8, 309.4+13.4, 306.9+12.1 mOsm/L for the omega-3 group (P=0.042 Week 6; 0.004 Week 12) OSDI place­bo group at base­line, week 6 and 12 was, 27.1±22.9, 19.6±17.0, and 22.0+19.3 com­pared to 32.4±19.2, 21±14.4, and 15.5+11.0 for the omega group. (P=0.285 Week 6; 0.002 Week 12) Tear break-up time place­bo group at base­line, week 6 and 12 was 4.61±2.04, 5.55±2.43 and 5.81+3.13 com­pared to 4.78±2.96, 6.64±3.17 and 8.25+4.78 for the omega group. (P=0.126 Week 6; 0.002 Week 12) Omega index lev­els sta­tis­ti­cal­ly improved at 12 weeks in the omega group vs place­bo (p<0.001).


This study demon­strat­ed that oral con­sump­tion of re-ester­i­fied omega-3 fat­ty acids (1680 mg EPA and 560 mg DHA once dai­ly for 12 weeks) is an effec­tive treat­ment of dry eyes and results in a sta­tis­ti­cal­ly sig­nif­i­cant improve­ment in tear osmo­lar­i­ty, OSDI, tear break-up time and omega index lev­els.

Clinical Trial Results

  • Sig­nif­i­cant improve­ment in tear osmo­lar­i­ty
  • Sig­nif­i­cant improve­ment in omega-3 index lev­els
  • Sig­nif­i­cant improve­ment in OSDI
  • Sig­nif­i­cant improve­ment in tear break-up time
July 24th, 2015|0 Comments

About the Author:

Born in Connecticut and raised in Upstate New York , Dr. Stetson graduated Cum Laude from Colgate University in New York, and then earned an MD degree with honors at the University of Vermont College of Medicine. He distinguished himself again in residency at the Albany Medical Center, where he obtained the highest percentile in the Ophthalmology Knowledge Assessment Examinations. Dr. Stetson has performed more than 50,000 refractive surgeries and has been on staff at Diamond Vision since 2004, before becoming Medical Director in 2006.


If you would like to schedule a free consultation or ask one of our amazing staff a quick question, text "Diamond Ready" to (917) 881-3938 between 9am-6pm (M-F) and we will be here to help you!